Publications by authors named "J P Machiels"
The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change.
Eur J Cancer
November 2024
Article Synopsis
- The study focused on establishing minimal important change (MIC) estimates for quality of life (QoL) in head and neck cancer patients using the EORTC QLQ-HN43 questionnaire.
- A total of 503 patients from 15 countries completed the questionnaire at three different time points during treatment, and results indicated varying MICs for different QoL domains such as swallowing, speech, and dry mouth.
- Findings revealed that MIC values for deterioration were generally higher than those for improvement, implying that a universal MIC or minimal detectable change (MDC) cannot be uniformly applied across all scales of the EORTC QLQ-HN43.
Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC).
Patients And Methods: Part 1 determined the recommended dose for expansion of T-DXd plus nivolumab. Part 2 evaluated efficacy and safety; the primary endpoint was confirmed objective response rate by independent central review.
Article Synopsis
- * Conducted from 2012 to 2020, the research involved 104 patients and found weak correlations for immune markers, particularly PD-L1 and T-cell densities, between the two types of samples.
- * Results indicated that higher immunoscores in surgical samples were associated with better overall and disease-free survival, suggesting their potential value in predicting outcomes for advanced OCSCC.
Article Synopsis
- Gestational trophoblastic neoplasia (GTN) is a rare condition with a nearly 100% cure rate for low-risk cases, but the article discusses a resistant case in a 28-year-old woman.
- The focus is on the emerging role of immunotherapy in GTN treatment, highlighting a failed trial with an immune checkpoint inhibitor.
- As a last resort, a combination therapy using Paclitaxel, Ifosfamide, Carboplatin, and Etoposide was administered to attempt a cure after rapid disease progression post-hysterectomy.
Background: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC.
Methods: In the randomised, double-blind, phase 3 KEYNOTE-412 trial, participants with newly diagnosed, high-risk, unresected locally advanced HNSCC from 130 medical centres globally were randomly assigned (1:1) to pembrolizumab (200 mg) plus chemoradiotherapy or placebo plus chemoradiotherapy.